Kardigan, INC

Kardigan, Inc. announced its second quarter 2026 financial results, detailing progress in its late-stage cardiovascular drug development programs and a robust cash position following its initial public offering.

Kardigan, Inc. details advancements in its cardiovascular drug pipeline, successful IPO, and robust cash position, while acknowledging ongoing development risks.

Perceptive Advisors Llc and 3 others reported changes in beneficial ownership of Kardigan, Inc. common stock on June 17, 2026.

Kardigan, Inc. (KARD) reports a significant acquisition of 3,125,000 common shares by HRTG GPE, LLC, a 10% owner and director, on June 22, 2026.

Kardigan, Inc. Director Paul Berns reported transactions involving common stock and restricted stock units, reflecting his beneficial ownership and investment activities.

ARCH Venture Partners XIII, LLC and affiliated entities report significant beneficial ownership and recent transactions in Kardigan, Inc. common stock.

Perceptive Advisors and affiliates report an 8.9% beneficial ownership stake in Kardigan, Inc. following the company's IPO.

Tassos Gianakakos reports beneficial ownership of 11.1% of Kardigan Inc. common stock as of June 30, 2026.

Jay Edelberg has reported beneficial ownership of 4,878,105 shares, representing 5.2% of Kardigan, Inc.'s common stock, as of June 30, 2026.

FMR LLC has reported a beneficial ownership of 10.3% in Kardigan Inc. as of July 31, 2026, indicating a substantial institutional holding.

FMR LLC, along with Abigail P. Johnson, has reported beneficial ownership of 10% of Kardigan Inc.'s common stock as of June 30, 2026.

HRTG entities and individuals report beneficial ownership of 18.2% of Kardigan, Inc. common stock, excluding certain warrant shares.